Fifth Third Bancorp
AXSM icon

Fifth Third Bancorp’s Axsome Therapeutics AXSM Stock Holding History

Fifth Third Bancorp’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74M Buy
16,214
+13,737
+555% +$2.37M 0.01% 1057
2025
Q4 		$452K Buy
2,477
+2,265
+1,068% +$316K ﹤0.01% 798
2025
Q3 		$25.7K Buy
212
+12
+6% +$1.35K ﹤0.01% 1783
2025
Q2 		$20.9K Hold
200
– – ﹤0.01% 1762
2025
Q1 		$23.3K Hold
200
– – ﹤0.01% 1707
2024
Q4 		$16.9K Hold
200
– – ﹤0.01% 1803
2024
Q3 		$18K Hold
200
– – ﹤0.01% 1808
2024
Q2 		$16.1K Hold
200
– – ﹤0.01% 1778
2024
Q1 		$16K Hold
200
– – ﹤0.01% 1724
2023
Q4 		$15.9K Sell
200
-200
-50% -$13.4K ﹤0.01% 1836
2023
Q3 		$28K Buy
400
+200
+100% +$15K ﹤0.01% 1609
2023
Q2 		$14.4K Hold
200
– – ﹤0.01% 1856
2023
Q1 		$12.3K Hold
200
– – ﹤0.01% 2019
2022
Q4 		$15.4K Hold
200
– – ﹤0.01% 1801
2022
Q3 		$9K Hold
200
– – ﹤0.01% 1969
2022
Q2 		$8K Buy
+200
New +$6.33K ﹤0.01% 2068

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fifth Third Bancorp's AXSM Position: Q1 2026 in Review

Fifth Third Bancorp increased its Axsome Therapeutics (AXSM) stake by 555% in Q1 2026, buying an estimated $2.37M and bringing the position to 16,214 shares worth $2.74M. The position accounts for 0.01% of the portfolio, ranked #1057.

Fifth Third Bancorp first reported a position in AXSM in Q2 2022 and has held it in 16 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Fifth Third Bancorp held 16,214 shares of Axsome Therapeutics worth $2.74M as of Q1 2026.
  • Fifth Third Bancorp bought 13,737 Axsome Therapeutics shares in Q1 2026, an estimated $2.37M.
  • Axsome Therapeutics made up 0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #1057 holding.
  • Fifth Third Bancorp first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.